BioticsAI CEO Reveals Blueprint for FDA Approval and Fundraising in Heavily Regulated Healthcare AI Space
BioticsAI CEO Robhy Bustami reveals strategy for FDA approval, fundraising, and team motivation in regulated healthcare AI, offering a blueprint for startups.
Breaking: BioticsAI CEO Shares Insider Strategy on Navigating Healthcare Red Tape
Boston, MA – In an exclusive interview released today, BioticsAI CEO Robhy Bustami laid out the company's playbook for securing FDA approval, raising capital, and keeping teams motivated amid the grueling reality of building in healthcare. The frank discussion, part of the Build Mode podcast series, offers a rare behind-the-scenes look at how startups can survive—and thrive—in one of the most regulated sectors.
The most critical takeaway: regulatory strategy must be baked in from day one, not treated as an afterthought. “We spent two years just understanding the FDA’s evolving expectations for AI-based medical devices,” Bustami said. “That upfront investment saved us years of rework later.”
Background: BioticsAI’s Journey So Far
BioticsAI develops AI-powered diagnostic tools for prenatal ultrasound interpretation. The company has raised multiple funding rounds from both venture capital and strategic investors. It received FDA clearance for its first product in 2023, a milestone that Bustami describes as “a validation of our approach but just the starting line.”
Like many healthcare AI startups, BioticsAI faced a maze of regulatory hurdles, including changing FDA guidance on algorithm updates and the need for real-world performance data. The company has navigated these challenges while maintaining a lean, focused team of about 20 employees.
What This Means for Healthcare AI Startups
Bustami’s candid account signals that the traditional “move fast and break things” mindset doesn’t work in healthcare. Instead, founders must embrace “structured agility” – iterative development within a compliant framework. The CEO stressed that fundraising in this sector also demands patience: “Investors want to see a clear path to market, not just a clever algorithm. That means having regulatory and clinical validation before you ask for their money.”
The interview highlights a widening gap between healthcare AI companies that treat regulation as a burden versus those that treat it as a competitive advantage. Bustami’s team, for example, turned FDA feedback sessions into product improvements, a strategy that accelerated their timeline.
Key Quotes from the Interview
“The hardest part isn’t the technology—it’s the uncertainty. Every time the FDA releases new draft guidance, you have to re-evaluate your whole plan. But we built a culture where that’s normal; nobody panics,” Bustami said. He added: “We hire for resilience, not just technical skill. Because in healthcare, your ‘ship date’ can be pushed back by years, and you need a team that doesn’t fall apart.”
On fundraising: “I tell every founder: raise more than you think you need, because the regulatory timeline is always longer than your spreadsheet predicts. We had to go back to investors twice for bridge rounds. Transparency is everything.”
The Fundraising Reality Check
Busti explained that while the current AI hype cycle has made fundraising easier for some, healthcare remains a tough sell. “Venture capitalists love the story of AI in radiology, but they get cold feet when they see the 18-month FDA review queue. We combat that by showing our real-world data from the early pilots—not just the technology demo.”
BioticsAI’s approach appears to be working. The company closed a Series B round earlier this year, though terms were not disclosed. Bustami credits a tiered funding strategy that combined nondilutive grants with equity rounds to stretch the runway.
Cutting Through Red Tape: Keeping the Team Motivated
A major theme of the interview was team morale. “In a startup, you celebrate small wins—a positive FDA meeting, a new hospital partner. But in healthcare, the big regulatory milestones are years apart. So we created internal ‘mini-launches’ every quarter to keep energy high,” Bustami said.
The CEO also emphasized the importance of mission-driven hiring. “Every employee here has a story about how medical imaging has affected their family. That emotional connection is what keeps people going when the paperwork piles up.”
Looking Ahead
BioticsAI is now working on expanding its platform to additional clinical indications and exploring international markets. Bustami hinted at a new partnership with a major health system that will be announced later this quarter.
For other founders in the space, his message is clear: “Regulation is not the enemy; it’s the proof that what you’re building matters. If it were easy, everyone would do it.”